These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 23143411)

  • 21. Extended release quetiapine fumarate in major depressive disorder: analysis in patients with anxious depression.
    Thase ME; Demyttenaere K; Earley WR; Gustafsson U; Udd M; Eriksson H
    Depress Anxiety; 2012 Jul; 29(7):574-86. PubMed ID: 22753280
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The role of extended-release quetiapine fumarate monotherapy in the treatment of patients with major depressive disorder.
    Weisler R; McIntyre RS
    Expert Rev Neurother; 2013 Nov; 13(11):1161-82. PubMed ID: 24175720
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of adjunctive antidepressant therapy with quetiapine on clinical outcome, quality of sleep and daytime motor activity in patients with treatment-resistant depression.
    Baune BT; Caliskan S; Todder D
    Hum Psychopharmacol; 2007 Jan; 22(1):1-9. PubMed ID: 17191266
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Quetiapine extended release: adjunctive treatment in major depressive disorder.
    Sanford M
    CNS Drugs; 2011 Sep; 25(9):803-13. PubMed ID: 21870891
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Extended-release quetiapine fumarate in the treatment of patients with major depressive disorder: adjunct therapy.
    Weisler R; McIntyre RS; Bauer M
    Expert Rev Neurother; 2013 Nov; 13(11):1183-200. PubMed ID: 24175721
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Extended release quetiapine fumarate as adjunct to antidepressant therapy in patients with major depressive disorder: pooled analyses of data in patients with anxious depression versus low levels of anxiety at baseline.
    Bandelow B; Bauer M; Vieta E; El-Khalili N; Gustafsson U; Earley WR; Eriksson H
    World J Biol Psychiatry; 2014 Feb; 15(2):155-66. PubMed ID: 24506289
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Adjunctive quetiapine targets self-harm behaviors in adolescent females with major depressive disorder.
    Good CR
    J Child Adolesc Psychopharmacol; 2006 Jun; 16(3):235-6. PubMed ID: 16768629
    [No Abstract]   [Full Text] [Related]  

  • 28. Factors Related to Early Clinical Effects of Quetiapine Extended-Release: A Multinational, Prospective, Observational Study.
    Molina L; Recinos B; Paz B; Rovelo M; Elias Rodriguez FE; Calderón J; Arellano A; Pomata S; Rey MV; Perez-Lloret S
    Clin Drug Investig; 2016 Jun; 36(6):491-7. PubMed ID: 27021967
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Double-blind, randomized study of extended release quetiapine fumarate (quetiapine XR) monotherapy in older patients with generalized anxiety disorder.
    Mezhebovsky I; Mägi K; She F; Datto C; Eriksson H
    Int J Geriatr Psychiatry; 2013 Jun; 28(6):615-25. PubMed ID: 23070803
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of extended-release quetiapine fumarate on long-term functioning and sleep quality in patients with Generalized Anxiety Disorder (GAD): data from a randomized-withdrawal, placebo-controlled maintenance study.
    Sheehan DV; Svedsäter H; Locklear JC; Eriksson H
    J Affect Disord; 2013 Dec; 151(3):906-13. PubMed ID: 24135509
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pooled analysis of sustained response rates for extended release quetiapine fumarate as monotherapy or adjunct to antidepressant therapy in patients with major depressive disorder.
    Vieta E; Bauer M; Montgomery S; McIntyre RS; Szamosi J; Earley WR; Eriksson H
    J Affect Disord; 2013 Sep; 150(2):639-43. PubMed ID: 23497790
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Extended-release quetiapine as monotherapy for the treatment of adults with acute mania: a randomized, double-blind, 3-week trial.
    Cutler AJ; Datto C; Nordenhem A; Minkwitz M; Acevedo L; Darko D
    Clin Ther; 2011 Nov; 33(11):1643-58. PubMed ID: 22054797
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Self-reported sedation profile of immediate-release quetiapine fumarate compared with extended-release quetiapine fumarate during dose initiation: a randomized, double-blind, crossover study in healthy adult subjects.
    Datto C; Berggren L; Patel JB; Eriksson H
    Clin Ther; 2009 Mar; 31(3):492-502. PubMed ID: 19393840
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sexual functioning in patients with major depressive disorder in randomized placebo-controlled studies of extended release quetiapine fumarate.
    Clayton AH; Locklear JC; Svedsäter H; McIntyre RS
    CNS Spectr; 2014 Apr; 19(2):182-96. PubMed ID: 24067192
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effectiveness of the extended release formulation of quetiapine as monotherapy for the treatment of acute bipolar depression.
    Suppes T; Datto C; Minkwitz M; Nordenhem A; Walker C; Darko D
    J Affect Disord; 2010 Feb; 121(1-2):106-15. PubMed ID: 19903574
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Quetiapine monotherapy in the treatment of depressive episodes of bipolar I and II disorder: Improvements in quality of life and quality of sleep.
    Endicott J; Paulsson B; Gustafsson U; Schiöler H; Hassan M
    J Affect Disord; 2008 Dec; 111(2-3):306-19. PubMed ID: 18774180
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The effects of quetiapine on sleep in recovering alcohol-dependent subjects: a pilot study.
    Chakravorty S; Hanlon AL; Kuna ST; Ross RJ; Kampman KM; Witte LM; Perlis ML; Oslin DW
    J Clin Psychopharmacol; 2014 Jun; 34(3):350-4. PubMed ID: 24747978
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A double-blind, placebo-controlled trial to assess the efficacy of quetiapine fumarate XR in very heavy-drinking alcohol-dependent patients.
    Litten RZ; Fertig JB; Falk DE; Ryan ML; Mattson ME; Collins JF; Murtaugh C; Ciraulo D; Green AI; Johnson B; Pettinati H; Swift R; Afshar M; Brunette MF; Tiouririne NA; Kampman K; Stout R;
    Alcohol Clin Exp Res; 2012 Mar; 36(3):406-16. PubMed ID: 21950727
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Extended-release quetiapine fumarate (quetiapine XR) versus risperidone in the treatment of depressive symptoms in patients with schizoaffective disorder or schizophrenia: a randomized, open-label, parallel-group, flexible-dose study.
    Di Fiorino M; Montagnani G; Trespi G; Kasper S
    Int Clin Psychopharmacol; 2014 May; 29(3):166-76. PubMed ID: 24681810
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Quetiapine XR efficacy and tolerability as monotherapy and as adjunctive treatment to conventional antidepressants in the acute and maintenance treatment of major depressive disorder: a review of registration trials.
    McIntyre RS; Muzina DJ; Adams A; Lourenco MT; Law CW; Soczynska JK; Woldeyohannes HO; Nathanson J; Kennedy SH
    Expert Opin Pharmacother; 2009 Dec; 10(18):3061-75. PubMed ID: 19954275
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.